{"nctId":"NCT00366548","briefTitle":"Study to Evaluate a 13-valent Pneumococcal Conjugate Vaccine in Infants","startDateStruct":{"date":"2006-11"},"conditions":["Vaccines, Pneumococcal"],"count":500,"armGroups":[{"label":"1","type":"EXPERIMENTAL","interventionNames":["Biological: 13 valent pneumococcal conjugate vaccine with Polysorbate 80"]},{"label":"2","type":"ACTIVE_COMPARATOR","interventionNames":["Biological: 13 valent pneumococcal conjugate vaccine without Polysorbate 80"]}],"interventions":[{"name":"13 valent pneumococcal conjugate vaccine with Polysorbate 80","otherNames":[]},{"name":"13 valent pneumococcal conjugate vaccine without Polysorbate 80","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion criteria:\n\n1. Aged 2 months (42 through 98 days) at the time of enrollment.\n2. Available for the entire study period and whose parent(s)/legal guardian(s) could be reached by telephone.\n3. In good health as determined by medical history, physical examination, and judgment of the investigator.\n4. Parent(s)/legal guardian(s) were able to complete all relevant study procedures during study participation.\n\nExclusion criteria:\n\n1. Previous vaccination with licensed or investigational pneumococcal vaccine.\n2. Previous vaccination with Hib conjugate, diphtheria, tetanus, pertussis, or polio vaccines.\n3. A previous anaphylactic reaction to any vaccine or vaccine-related component.\n4. Contraindication to vaccination with Hib conjugate, diphtheria, tetanus, pertussis, polio, hepatitis B, or pneumococcal vaccines.\n5. Bleeding diathesis or condition associated with prolonged bleeding time that would contraindicate intramuscular injection.\n6. Known or suspected immune deficiency or suppression.\n7. History of culture-proven invasive disease caused by S pneumoniae.\n8. Major known congenital malformation or serious chronic disorder.\n9. Significant neurological disorder or history of seizure (including febrile seizure), or significant stable or evolving disorders (such as cerebral palsy, encephalopathy, or hydrocephalus), or other significant disorders. This did not include resolving syndromes because of birth trauma such as Erb palsy.\n10. Receipt of blood products or γ-globulin (including hepatitis B immunoglobulin and monoclonal antibodies \\[eg, Synagis\\]).","healthyVolunteers":true,"sex":"ALL","minimumAge":"42 Days","maximumAge":"98 Days","stdAges":["CHILD"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Participants Achieving Antibody Level ≥0.35μg/mL in 13vPnC+P80 Group Relative to 13vPnC-80 Group After the Infant Series","description":"Percentages of participants achieving World Health Organization (WHO) predefined antibody threshold ≥0.35μg/mL along with the corresponding 95% CI for the 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (serotypes 1, 3, 5, 6A, 7F, and 19A) are presented.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"93.3","spread":null},{"groupId":"OG001","value":"94.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"60.9","spread":null},{"groupId":"OG001","value":"66.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"97.1","spread":null},{"groupId":"OG001","value":"97.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"94.5","spread":null},{"groupId":"OG001","value":"97.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"97.9","spread":null},{"groupId":"OG001","value":"97.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"95.8","spread":null},{"groupId":"OG001","value":"98.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"86.1","spread":null},{"groupId":"OG001","value":"92.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"95.8","spread":null},{"groupId":"OG001","value":"92.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"97.9","spread":null},{"groupId":"OG001","value":"99.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"94.1","spread":null},{"groupId":"OG001","value":"92.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"86.6","spread":null},{"groupId":"OG001","value":"86.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"98.7","spread":null},{"groupId":"OG001","value":"99.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"98.7","spread":null},{"groupId":"OG001","value":"100.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Achieving Antibody Level ≥ 0.35 μg/mL in the 13vPnC Group After the Toddler Dose","description":"Percentages of participants achieving World Health Organization (WHO) predefined antibody threshold ≥ 0.35 μg/mL along with the corresponding 95% CI for the 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (serotypes 1, 3, 5, 6A, 7F, and 19A) are presented.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"99.6","spread":null},{"groupId":"OG001","value":"99.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"99.6","spread":null},{"groupId":"OG001","value":"99.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"99.6","spread":null},{"groupId":"OG001","value":"100.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"99.6","spread":null},{"groupId":"OG001","value":"99.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null},{"groupId":"OG001","value":"99.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"99.1","spread":null},{"groupId":"OG001","value":"98.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"98.7","spread":null},{"groupId":"OG001","value":"99.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null},{"groupId":"OG001","value":"99.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"95.1","spread":null},{"groupId":"OG001","value":"94.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"99.6","spread":null},{"groupId":"OG001","value":"100.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"99.6","spread":null},{"groupId":"OG001","value":"100.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null},{"groupId":"OG001","value":"100.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null},{"groupId":"OG001","value":"100.0","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Percent of Participants Reporting Pre-Specified Local Reactions","description":"Local reactions were collected using an electronic diary. Tenderness was scaled as Any (tenderness present); Significant (Sig) (present and interfered with limb movement). Swelling and redness were scaled as Any (swelling or redness present); Mild (0.5 centimeters \\[cm\\] to 2.0 cm); Moderate (Mod) (2.5 to 7.0 cm); Severe (\\>7.0 cm). Participants may be represented in more than 1 category.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"27.7","spread":null},{"groupId":"OG001","value":"32.9","spread":null},{"groupId":"OG002","value":"26.8","spread":null},{"groupId":"OG003","value":"32.8","spread":null},{"groupId":"OG004","value":"24.8","spread":null},{"groupId":"OG005","value":"23.1","spread":null},{"groupId":"OG006","value":"42.1","spread":null},{"groupId":"OG007","value":"43.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.1","spread":null},{"groupId":"OG001","value":"4.3","spread":null},{"groupId":"OG002","value":"0.9","spread":null},{"groupId":"OG003","value":"0.5","spread":null},{"groupId":"OG004","value":"1.5","spread":null},{"groupId":"OG005","value":"1.9","spread":null},{"groupId":"OG006","value":"2.5","spread":null},{"groupId":"OG007","value":"1.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"22.9","spread":null},{"groupId":"OG001","value":"30.5","spread":null},{"groupId":"OG002","value":"25.0","spread":null},{"groupId":"OG003","value":"36.4","spread":null},{"groupId":"OG004","value":"36.7","spread":null},{"groupId":"OG005","value":"38.2","spread":null},{"groupId":"OG006","value":"29.9","spread":null},{"groupId":"OG007","value":"34.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"18.2","spread":null},{"groupId":"OG001","value":"24.2","spread":null},{"groupId":"OG002","value":"20.3","spread":null},{"groupId":"OG003","value":"31.9","spread":null},{"groupId":"OG004","value":"32.5","spread":null},{"groupId":"OG005","value":"33.5","spread":null},{"groupId":"OG006","value":"26.6","spread":null},{"groupId":"OG007","value":"29.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11.9","spread":null},{"groupId":"OG001","value":"14.4","spread":null},{"groupId":"OG002","value":"11.2","spread":null},{"groupId":"OG003","value":"14.3","spread":null},{"groupId":"OG004","value":"13.9","spread":null},{"groupId":"OG005","value":"17.5","spread":null},{"groupId":"OG006","value":"12.2","spread":null},{"groupId":"OG007","value":"19.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":null},{"groupId":"OG001","value":"0.0","spread":null},{"groupId":"OG002","value":"0.0","spread":null},{"groupId":"OG003","value":"0.0","spread":null},{"groupId":"OG004","value":"0.0","spread":null},{"groupId":"OG005","value":"0.0","spread":null},{"groupId":"OG006","value":"0.0","spread":null},{"groupId":"OG007","value":"0.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"29.8","spread":null},{"groupId":"OG001","value":"39.5","spread":null},{"groupId":"OG002","value":"38.8","spread":null},{"groupId":"OG003","value":"48.5","spread":null},{"groupId":"OG004","value":"46.8","spread":null},{"groupId":"OG005","value":"50.0","spread":null},{"groupId":"OG006","value":"42.1","spread":null},{"groupId":"OG007","value":"52.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"28.2","spread":null},{"groupId":"OG001","value":"35.7","spread":null},{"groupId":"OG002","value":"38.4","spread":null},{"groupId":"OG003","value":"47.0","spread":null},{"groupId":"OG004","value":"46.5","spread":null},{"groupId":"OG005","value":"46.9","spread":null},{"groupId":"OG006","value":"35.8","spread":null},{"groupId":"OG007","value":"46.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.1","spread":null},{"groupId":"OG001","value":"4.3","spread":null},{"groupId":"OG002","value":"1.4","spread":null},{"groupId":"OG003","value":"3.2","spread":null},{"groupId":"OG004","value":"3.9","spread":null},{"groupId":"OG005","value":"9.0","spread":null},{"groupId":"OG006","value":"12.8","spread":null},{"groupId":"OG007","value":"19.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":null},{"groupId":"OG001","value":"0.0","spread":null},{"groupId":"OG002","value":"0.0","spread":null},{"groupId":"OG003","value":"0.0","spread":null},{"groupId":"OG004","value":"0.0","spread":null},{"groupId":"OG005","value":"0.0","spread":null},{"groupId":"OG006","value":"0.0","spread":null},{"groupId":"OG007","value":"0.6","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Percentage of Participants Reporting Pre-Specified Systemic Events","description":"Systemic events (fever \\[Fv\\] ≥ 37.5 degrees Celsius \\[C\\], fever ≥ 38 C but ≤ 39 C, fever \\>39 C but ≤ 40 C, fever \\> 40 C, decreased (decr)appetite, irritability, increased (incr)sleep, decreased sleep, hives, use of medication (meds) to treat symptoms (sx), and use of medication to prevent symptoms) were reported using an electronic diary. Participants may be represented in more than 1 category.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"14.0","spread":null},{"groupId":"OG001","value":"16.2","spread":null},{"groupId":"OG002","value":"18.3","spread":null},{"groupId":"OG003","value":"17.0","spread":null},{"groupId":"OG004","value":"19.7","spread":null},{"groupId":"OG005","value":"20.6","spread":null},{"groupId":"OG006","value":"22.9","spread":null},{"groupId":"OG007","value":"18.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.4","spread":null},{"groupId":"OG001","value":"0.4","spread":null},{"groupId":"OG002","value":"0.9","spread":null},{"groupId":"OG003","value":"0.5","spread":null},{"groupId":"OG004","value":"1.0","spread":null},{"groupId":"OG005","value":"0.9","spread":null},{"groupId":"OG006","value":"2.5","spread":null},{"groupId":"OG007","value":"1.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":null},{"groupId":"OG001","value":"0.0","spread":null},{"groupId":"OG002","value":"0.0","spread":null},{"groupId":"OG003","value":"0.0","spread":null},{"groupId":"OG004","value":"0.0","spread":null},{"groupId":"OG005","value":"0.0","spread":null},{"groupId":"OG006","value":"0.0","spread":null},{"groupId":"OG007","value":"0.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"21.5","spread":null},{"groupId":"OG001","value":"22.4","spread":null},{"groupId":"OG002","value":"16.3","spread":null},{"groupId":"OG003","value":"24.1","spread":null},{"groupId":"OG004","value":"21.4","spread":null},{"groupId":"OG005","value":"20.7","spread":null},{"groupId":"OG006","value":"26.2","spread":null},{"groupId":"OG007","value":"29.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"55.0","spread":null},{"groupId":"OG001","value":"55.2","spread":null},{"groupId":"OG002","value":"51.7","spread":null},{"groupId":"OG003","value":"53.9","spread":null},{"groupId":"OG004","value":"45.6","spread":null},{"groupId":"OG005","value":"50.0","spread":null},{"groupId":"OG006","value":"49.5","spread":null},{"groupId":"OG007","value":"56.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"46.3","spread":null},{"groupId":"OG001","value":"52.5","spread":null},{"groupId":"OG002","value":"35.9","spread":null},{"groupId":"OG003","value":"39.3","spread":null},{"groupId":"OG004","value":"25.8","spread":null},{"groupId":"OG005","value":"27.6","spread":null},{"groupId":"OG006","value":"19.0","spread":null},{"groupId":"OG007","value":"30.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"35.7","spread":null},{"groupId":"OG001","value":"29.7","spread":null},{"groupId":"OG002","value":"24.7","spread":null},{"groupId":"OG003","value":"26.4","spread":null},{"groupId":"OG004","value":"25.4","spread":null},{"groupId":"OG005","value":"24.4","spread":null},{"groupId":"OG006","value":"19.4","spread":null},{"groupId":"OG007","value":"25.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"14.0","spread":null},{"groupId":"OG001","value":"16.6","spread":null},{"groupId":"OG002","value":"15.3","spread":null},{"groupId":"OG003","value":"16.8","spread":null},{"groupId":"OG004","value":"15.1","spread":null},{"groupId":"OG005","value":"14.7","spread":null},{"groupId":"OG006","value":"21.5","spread":null},{"groupId":"OG007","value":"15.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"14.5","spread":null},{"groupId":"OG001","value":"15.8","spread":null},{"groupId":"OG002","value":"16.4","spread":null},{"groupId":"OG003","value":"15.2","spread":null},{"groupId":"OG004","value":"15.1","spread":null},{"groupId":"OG005","value":"10.6","spread":null},{"groupId":"OG006","value":"18.7","spread":null},{"groupId":"OG007","value":"15.2","spread":null}]}]}]},{"type":"PRIMARY","title":"Geometric Mean Antibody Concentration (GMC) in 13vPnC+P80 Group Relative to 13vPnC-P80 Group After the 3-Dose Infant Series","description":"GMC as measured by enzyme-linked immunosorbent assay (ELISA) for 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (Serotypes 1, 3, 5, 6A, 7F, and 19A) are presented.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.47","spread":null},{"groupId":"OG001","value":"1.53","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.51","spread":null},{"groupId":"OG001","value":"0.57","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.46","spread":null},{"groupId":"OG001","value":"1.51","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.37","spread":null},{"groupId":"OG001","value":"2.48","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.84","spread":null},{"groupId":"OG001","value":"1.87","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.46","spread":null},{"groupId":"OG001","value":"1.75","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.93","spread":null},{"groupId":"OG001","value":"1.11","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.39","spread":null},{"groupId":"OG001","value":"1.48","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.50","spread":null},{"groupId":"OG001","value":"1.62","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.26","spread":null},{"groupId":"OG001","value":"1.30","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.99","spread":null},{"groupId":"OG001","value":"1.04","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.98","spread":null},{"groupId":"OG001","value":"1.89","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.68","spread":null},{"groupId":"OG001","value":"2.94","spread":null}]}]}]},{"type":"SECONDARY","title":"Geometric Mean Antibody Concentration (GMC) in 13vPnC Group Relative After the Toddler Dose","description":"GMC as measured by enzyme-linked immunosorbent assay (ELISA) for 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (Serotypes 1, 3, 5, 6A, 7F, and 19A) are presented.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.25","spread":null},{"groupId":"OG001","value":"5.38","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9.89","spread":null},{"groupId":"OG001","value":"10.65","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.01","spread":null},{"groupId":"OG001","value":"3.10","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11.72","spread":null},{"groupId":"OG001","value":"11.95","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.40","spread":null},{"groupId":"OG001","value":"3.10","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9.63","spread":null},{"groupId":"OG001","value":"10.27","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.88","spread":null},{"groupId":"OG001","value":"4.15","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.03","spread":null},{"groupId":"OG001","value":"6.11","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.09","spread":null},{"groupId":"OG001","value":"1.16","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.80","spread":null},{"groupId":"OG001","value":"3.98","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.48","spread":null},{"groupId":"OG001","value":"8.19","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.36","spread":null},{"groupId":"OG001","value":"4.95","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"13.20","spread":null},{"groupId":"OG001","value":"13.02","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":15,"n":249},"commonTop":["Irritability","Increased sleep","Erythema (Any)","Erythema (Mild)","Tenderness (Any)"]}}}